Drugs / Inactivated Rabies Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04270838 | Feb 2022 → Sep 2028 expected | rabies | University of Oxford | Active not recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT04162600 Background | Jan 2020 → Jul 2024 | rabies | University of Oxford | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT07168018 Comparator | Dec 2025 → Mar 2026 overdue | rabies | University of Oxford | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inactivated Rabies Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04162600 ↗ |
| Known as | IRV | “Coadministration of ChAdOx2 RabG and licensed inactivated rabies vaccine (IRV)” NCT07168018 ↗ |
| Modality | Vaccine | “an existing rabies vaccine” NCT04162600 ↗ |
| Route | Intramuscular | “licensed rabies vaccine will be given either intramuscularly (i.e., for the intervention group) or by intradermal injection (i.e., for the control group)” NCT07168018 ↗ |